5-(4-碘苯基)异恶唑 | 160377-48-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-(4-碘苯基)异恶唑
• 英文名称: 5-(4-iodophenyl)isoxazole
• 英文别名: 5-(4-iodophenyl)-isoxazole；5-(4-iodophenyl)-1,2-oxazole
• CAS: 160377-48-0
• 化学式: C₉H₆INO
• 分子量: 271.057
• InChiKey: TYNWYXFACGRXMG-UHFFFAOYSA-N

物化性质

• 熔点：
  139 °C

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090
• 安全说明：
  S24/25

反应信息

• 作为反应物：
  描述：

  5-(4-碘苯基)异恶唑 、 3,17β-bis(hydroxy)-7α-(6-hexynyl)-estra-1,3,5(10)-triene 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 以82%的产率得到3,17β-bis(hydroxy)-7α-[6-(4-isoxazol-5-yl-phenyl)-hex-5-ynyl]estra-1,3,5(10)-triene
  参考文献：
  名称：

  Synthesis of Novel Estrogen Receptor Antagonists Using Metal-Catalyzed Coupling Reactions and Characterization of Their Biological Activity

  摘要：

  Estrogen receptor (ER) antagonists are valuable in the treatment of ER-positive human breast cancer. In this study, we designed and synthesized nine new derivatives of 17 beta-estradiol (E-2) with a bulky side chain attached to its C-7 alpha position, and determined their ER antagonistic activity using in vitro bioassays. Four of the derivatives showed a strong inhibition of ER alpha transactivation activity in a luciferase reporter assay and blocked ER alpha interactions with coactivators. Similarly, these derivatives also strongly inhibited the growth of the ER alpha-positive human breast cancer cells. Computational docking analysis was conducted to model the interaction of these antagonists with the human ER alpha and showed that they could tightly bind to the ER alpha in a manner similar to that of ICI-182,780, a pure ER antagonist. These results provide an example that attachment of a bulky side chain to the C-7 alpha position of E-2 can produce ER antagonists with ER affinity comparable to that of ICI-182, 780.

  DOI：

  10.1021/jm3013773
• 作为产物：
  描述：

  (E)-3-(dimethylamino)-1-(4-iodophenyl)prop-2-en-1-one 在 盐酸羟胺 作用下， 以 1,4-二氧六环 、 水 、 乙酸乙酯 为溶剂， 生成 5-(4-碘苯基)异恶唑
  参考文献：
  名称：

  Quinuclidine derivatives as squalene synthase inhibitors

  摘要：

  化合物的化学式（I）及其药用盐，其中R.sup.1为氢或羟基；R.sup.2为氢；或R.sup.1和R.sup.2结合在一起，使得CR.sup.1 -CR.sup.2为双键；X从--CH.sub.2 CH.sub.2 --，--CH.dbd.CH--，--C.tbd.C--，--CH.sub.2 O--，--CH.sub.2 NH--，--NHCH.sub.2 --，--CH.sub.2 CO--，--COCH.sub.2 --，--CH.sub.2 S--和--SCH.sub.2 --中选择；Ar.sup.1为苯基；Ar.sup.2为杂环芳基；其中Ar.sup.1和Ar.sup.2中的一个或两个可以选择性地带有一个或多个取代基，取代基独立地从卤素，羟基，氨基，硝基，氰基，羧基，氨基甲酰基，烷基，烯基，炔基，烷氧基，烷基氨基，二烷基氨基，N-烷基氨基甲酰基，二N,N-烷基氨基甲酰基，烷氧羰基，烷基硫醚，烷基砜基，卤代烷基，羧基烷基和烷酰胺基中独立选择；但当R.sup.1为羟基时，X不可从--NHCH.sub.2 --和--SCH.sub.2 --中选择；是皂化酶的抑制剂，因此在治疗降低胆固醇有益的医疗状况中有用，如高胆固醇血症和动脉粥样硬化。还描述了制备这些衍生物的方法，含有它们的药物组合物以及它们在医学中的用途。

  公开号：

  US05714496A1

文献信息

• Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
  申请人：Borchardt Allen

  公开号：US20050176701A1

  公开（公告）日：2005-08-11

  The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R 1 and R 2 , are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula 1, and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.

  这项发明涉及公式1的化合物，以及其药学上可接受的盐、溶剂化合物、前药和代谢物，其中W、Z、R1和R2如本文所定义。该发明还涉及通过给哺乳动物施用公式1的化合物来治疗丙型肝炎病毒的方法，以及用于治疗这类疾病的含有公式1化合物的药物组合物。该发明还涉及制备公式1化合物的方法。
• Catalytic Synthesis of Potassium Acyltrifluoroborates (KATs) through Chemoselective Cross‐Coupling with a Bifunctional Reagent
  作者：Dino Wu、Nicole A. Fohn、Jeffrey W. Bode

  DOI：10.1002/anie.201904576

  日期：2019.8.5

  Potassium acyltrifluoroborates (KATs) are increasingly important functional groups, and general methods for their preparation are of great current interest. We report a bifunctional iminium reagent bearing both a tin nucleophile and a trifluoroborate, which was applied in chemoselective Pd0‐catalyzed Migita–Kosugi–Stille cross‐coupling reactions owith aryl and vinyl halides. This method gives access

  酰基三氟硼酸钾（KAT）是越来越重要的官能团，制备它们的通用方法引起了人们的极大兴趣。我们报道了一种带有锡亲核试剂和三氟硼酸盐的双功能亚胺试剂，该试剂已用于Pd 0催化的Migita-Kosugi-Stille交叉偶联反应，以及芳基和卤代乙烯。这种方法可以访问以前难以获得的芳族和α，β-不饱和酰基三氟硼酸酯，包括氨基酸衍生的KAT的前体。
• INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME
  申请人：Borchardt Allen

  公开号：US20060189681A1

  公开（公告）日：2006-08-24

  The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R 1 and R 2 , are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula 1, and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.

  本发明涉及式1的化合物以及其药学上可接受的盐、溶剂合物、前药和代谢物，其中W、Z、R1和R2如本文所定义。本发明还涉及通过给哺乳动物投予式1的化合物来治疗丙型肝炎病毒的方法，以及包含式1的化合物的用于治疗此类疾病的制药组合物。本发明还涉及制备式1的化合物的方法。
• 1,3,8-Triazaspiro[4.5]decane-2,4-diones as Efficacious Pan-Inhibitors of Hypoxia-Inducible Factor Prolyl Hydroxylase 1–3 (HIF PHD1–3) for the Treatment of Anemia
  作者：Petr Vachal、Shouwu Miao、Joan M. Pierce、Deodial Guiadeen、Vincent J. Colandrea、Matthew J. Wyvratt、Scott P. Salowe、Lisa M. Sonatore、James A. Milligan、Richard Hajdu、Anantha Gollapudi、Carol A. Keohane、Russell B. Lingham、Suzanne M. Mandala、Julie A. DeMartino、Xinchun Tong、Michael Wolff、Dietrich Steinhuebel、Gerard R. Kieczykowski、Fred J. Fleitz、Kevin Chapman、John Athanasopoulos、Gregory Adam、Can D. Akyuz、Dhirendra K. Jena、Jeffrey W. Lusen、Juncai Meng、Benjamin D. Stein、Lei Xia、Edward C. Sherer、Jeffrey J. Hale

  DOI：10.1021/jm201542d

  日期：2012.4.12

  The discovery of 1,3,8-triazaspiro[4.5]decane-2,4-diones (spirohydantoins) as a structural class of pan-inhibitors of the prolyl hydroxylase (PHD) family of enzymes for the treatment of anemia is described. The initial hit class, spirooxindoles, was identified through affinity selection mass spectrometry (AS-MS) and optimized for PHD2 inhibition and optimal PK/PD profile (short-acting PHDi inhibitors). 1,3,8-Triazaspiro[4.5]decane-2,4-diones (spirohydantoins) were optimized as an advanced lead class derived from the original spiroindole hit. A new set of general conditions for C-N coupling, developed using a high-throughput experimentation (HTE) technique, enabled a full SAR analysis of the spirohydantoins. This rapid and directed SAR exploration has resulted in the first reported examples of hydantoin derivatives with good PK in preclinical species. Potassium channel off-target activity (hERG) was successfully eliminated through the systematic introduction of acidic functionality to the molecular structure. Undesired upregulation of alanine aminotransferese (ALT) liver enzymes was mitigated and a robust on-/off-target margin was achieved. Spirohydantoins represent a class of highly efficacious, short-acting PHD1-3 inhibitors causing a robust erythropoietin (EPO) upregulation in vivo in multiple preclinical species. This profile deems spirohydantoins as attractive short-acting PHDi inhibitors with the potential for treatment of anemia.
• QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS
  申请人：ZENECA LIMITED

  公开号：EP0656897A1

  公开（公告）日：1995-06-14